Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses.
Influenza vaccine effectiveness (VE) is generally interpreted in the context of vaccine match/mismatch to circulating strains with evolutionary drift in the latter invoked to explain reduced protection. During the 2012-13 season, however, detailed genotypic and phenotypic characterization shows that...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3965421?pdf=render |
| _version_ | 1818286808065114112 |
|---|---|
| author | Danuta M Skowronski Naveed Z Janjua Gaston De Serres Suzana Sabaiduc Alireza Eshaghi James A Dickinson Kevin Fonseca Anne-Luise Winter Jonathan B Gubbay Mel Krajden Martin Petric Hugues Charest Nathalie Bastien Trijntje L Kwindt Salaheddin M Mahmud Paul Van Caeseele Yan Li |
| author_facet | Danuta M Skowronski Naveed Z Janjua Gaston De Serres Suzana Sabaiduc Alireza Eshaghi James A Dickinson Kevin Fonseca Anne-Luise Winter Jonathan B Gubbay Mel Krajden Martin Petric Hugues Charest Nathalie Bastien Trijntje L Kwindt Salaheddin M Mahmud Paul Van Caeseele Yan Li |
| author_sort | Danuta M Skowronski |
| collection | DOAJ |
| description | Influenza vaccine effectiveness (VE) is generally interpreted in the context of vaccine match/mismatch to circulating strains with evolutionary drift in the latter invoked to explain reduced protection. During the 2012-13 season, however, detailed genotypic and phenotypic characterization shows that low VE was instead related to mutations in the egg-adapted H3N2 vaccine strain rather than antigenic drift in circulating viruses.Component-specific VE against medically-attended, PCR-confirmed influenza was estimated in Canada by test-negative case-control design. Influenza A viruses were characterized genotypically by amino acid (AA) sequencing of established haemagglutinin (HA) antigenic sites and phenotypically through haemagglutination inhibition (HI) assay. H3N2 viruses were characterized in relation to the WHO-recommended, cell-passaged vaccine prototype (A/Victoria/361/2011) as well as the egg-adapted strain as per actually used in vaccine production. Among the total of 1501 participants, influenza virus was detected in 652 (43%). Nearly two-thirds of viruses typed/subtyped were A(H3N2) (394/626; 63%); the remainder were A(H1N1)pdm09 (79/626; 13%), B/Yamagata (98/626; 16%) or B/Victoria (54/626; 9%). Suboptimal VE of 50% (95%CI: 33-63%) overall was driven by predominant H3N2 activity for which VE was 41% (95%CI: 17-59%). All H3N2 field isolates were HI-characterized as well-matched to the WHO-recommended A/Victoria/361/2011 prototype whereas all but one were antigenically distinct from the egg-adapted strain as per actually used in vaccine production. The egg-adapted strain was itself antigenically distinct from the WHO-recommended prototype, and bore three AA mutations at antigenic sites B [H156Q, G186V] and D [S219Y]. Conversely, circulating viruses were identical to the WHO-recommended prototype at these positions with other genetic variation that did not affect antigenicity. VE was 59% (95%CI:16-80%) against A(H1N1)pdm09, 67% (95%CI: 30-85%) against B/Yamagata (vaccine-lineage) and 75% (95%CI: 29-91%) against B/Victoria (non-vaccine-lineage) viruses.These findings underscore the need to monitor vaccine viruses as well as circulating strains to explain vaccine performance. Evolutionary drift in circulating viruses cannot be regulated, but influential mutations introduced as part of egg-based vaccine production may be amenable to improvements. |
| first_indexed | 2024-12-13T01:30:28Z |
| format | Article |
| id | doaj.art-6ec04d279c424b7f886653fb7c6f441f |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T01:30:28Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-6ec04d279c424b7f886653fb7c6f441f2022-12-22T00:04:01ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0193e9215310.1371/journal.pone.0092153Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses.Danuta M SkowronskiNaveed Z JanjuaGaston De SerresSuzana SabaiducAlireza EshaghiJames A DickinsonKevin FonsecaAnne-Luise WinterJonathan B GubbayMel KrajdenMartin PetricHugues CharestNathalie BastienTrijntje L KwindtSalaheddin M MahmudPaul Van CaeseeleYan LiInfluenza vaccine effectiveness (VE) is generally interpreted in the context of vaccine match/mismatch to circulating strains with evolutionary drift in the latter invoked to explain reduced protection. During the 2012-13 season, however, detailed genotypic and phenotypic characterization shows that low VE was instead related to mutations in the egg-adapted H3N2 vaccine strain rather than antigenic drift in circulating viruses.Component-specific VE against medically-attended, PCR-confirmed influenza was estimated in Canada by test-negative case-control design. Influenza A viruses were characterized genotypically by amino acid (AA) sequencing of established haemagglutinin (HA) antigenic sites and phenotypically through haemagglutination inhibition (HI) assay. H3N2 viruses were characterized in relation to the WHO-recommended, cell-passaged vaccine prototype (A/Victoria/361/2011) as well as the egg-adapted strain as per actually used in vaccine production. Among the total of 1501 participants, influenza virus was detected in 652 (43%). Nearly two-thirds of viruses typed/subtyped were A(H3N2) (394/626; 63%); the remainder were A(H1N1)pdm09 (79/626; 13%), B/Yamagata (98/626; 16%) or B/Victoria (54/626; 9%). Suboptimal VE of 50% (95%CI: 33-63%) overall was driven by predominant H3N2 activity for which VE was 41% (95%CI: 17-59%). All H3N2 field isolates were HI-characterized as well-matched to the WHO-recommended A/Victoria/361/2011 prototype whereas all but one were antigenically distinct from the egg-adapted strain as per actually used in vaccine production. The egg-adapted strain was itself antigenically distinct from the WHO-recommended prototype, and bore three AA mutations at antigenic sites B [H156Q, G186V] and D [S219Y]. Conversely, circulating viruses were identical to the WHO-recommended prototype at these positions with other genetic variation that did not affect antigenicity. VE was 59% (95%CI:16-80%) against A(H1N1)pdm09, 67% (95%CI: 30-85%) against B/Yamagata (vaccine-lineage) and 75% (95%CI: 29-91%) against B/Victoria (non-vaccine-lineage) viruses.These findings underscore the need to monitor vaccine viruses as well as circulating strains to explain vaccine performance. Evolutionary drift in circulating viruses cannot be regulated, but influential mutations introduced as part of egg-based vaccine production may be amenable to improvements.http://europepmc.org/articles/PMC3965421?pdf=render |
| spellingShingle | Danuta M Skowronski Naveed Z Janjua Gaston De Serres Suzana Sabaiduc Alireza Eshaghi James A Dickinson Kevin Fonseca Anne-Luise Winter Jonathan B Gubbay Mel Krajden Martin Petric Hugues Charest Nathalie Bastien Trijntje L Kwindt Salaheddin M Mahmud Paul Van Caeseele Yan Li Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS ONE |
| title | Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. |
| title_full | Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. |
| title_fullStr | Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. |
| title_full_unstemmed | Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. |
| title_short | Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. |
| title_sort | low 2012 13 influenza vaccine effectiveness associated with mutation in the egg adapted h3n2 vaccine strain not antigenic drift in circulating viruses |
| url | http://europepmc.org/articles/PMC3965421?pdf=render |
| work_keys_str_mv | AT danutamskowronski low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses AT naveedzjanjua low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses AT gastondeserres low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses AT suzanasabaiduc low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses AT alirezaeshaghi low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses AT jamesadickinson low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses AT kevinfonseca low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses AT anneluisewinter low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses AT jonathanbgubbay low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses AT melkrajden low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses AT martinpetric low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses AT huguescharest low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses AT nathaliebastien low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses AT trijntjelkwindt low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses AT salaheddinmmahmud low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses AT paulvancaeseele low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses AT yanli low201213influenzavaccineeffectivenessassociatedwithmutationintheeggadaptedh3n2vaccinestrainnotantigenicdriftincirculatingviruses |